rereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico

Type or print name

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FEDER ET AL.

APPLICATION NO: 10/075,846

FILED: FEBRUARY 13, 2002

FOR: POLYNUCLEOTIDES ENCODING A NOVEL GLYCINE RECEPTOR

ALPHA SUBUNIT SPLICE VARIANT EXPRESSED IN THE

GASTROINTESTINAL TRACT, HGRA4SV

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-5289

Date: 5-6-04

Stephen C. D'Amico Agent for Applicants Reg. No. 46,652



CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Stephen C. D'Amico

Type or print name

2 to see

5-6-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FEDER ET AL.

APPLICATION NO: 10/075,846 FILED: FEBRUARY 13, 2002

FOR: POLYNUCLEOTIDES ENCODING A NOVEL GLYCINE RECEPTOR

ALPHA SUBUNIT SPLICE VARIANT EXPRESSED IN THE

GASTROINTESTINAL TRACT, HGRA4SV

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

05/11/2004 AADOF01 00000056 193880 10075846

01 FC:1806

180.00 DA

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-5289

Date: 5-6-04

Stephen C. D'Amico Agent for Applicants Reg. No. 46,652 FORM PTO-1449 (REV. 7-85)

EXAMINER

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

E (Use several sheets if necessary)

ATTY. DOCKET NO. D0079 NP APPLICATION NO. 10/075,846 APPLICANT FEDER ET AL. FILING DATE FEBRUARY 13, 2002

Group

U.S.	PAT	FNT	DOC	LIME	NTS
U.U.				UITIL	_1110

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CL	uss subci	ASS	FILING DATE
	AA							
	AB							
-	AC							
	AD							******
	AE							
	AF							<u>.</u>
	AG							· · · · · ·
	АН							
	Al							
	AJ							1 N.
	AK							
	AL							
			FOREIG	N PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRA YES	NSLATION NO
	AM							
	AN							
	AO							
	AP							
	AQ							
		OTHER DOCL	JMENTS (ncluding Author, Title, Date, Pertiner	nt pages, E	tc.)	•	
:	AR	NCBI Accession No. P	23416 (gi:1	21578), Grenningloh, et al., Mar	ch 15, 20	004		
	AS	Database Embl, EBI, F RP5-1055C14 on chro	linxton, Car mosome Xo	nbridgeshire,UK; April 10, 1999, 22.1-22.3." Database accession	"Human on no. AL	DNA seque .049610, XF	ence fr 200226	om clone 971
	АТ	Cummings, et al., "Ana Gene and Exclusion of 78, pp. 176-178 (1998)	This Gene	Genomic Structure of the Huma as a Candidate for Rett Syndro	in Glycine me", Ame	e Receptor of Med	α2 Sub I. Gene	ounit etics, Vol.

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

DATE CONSIDERED

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(the several sheets if necessary)

ATTY. DOCKET NO. D0079 NP APPLICATION NO. 10/075,846 APPLICANT FEDER ET AL. FILING DATE FEBRUARY 13, 2002

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

TETRAL		(
	2AA	Strausberg, et al., "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences", PNAS, Vol. 99 (26), pp. 16899-16903 (2002)							
	2AB	Monani, et al., "Structure of the Human α ₂ Subunit Gene of the Glycine Receptor-Use of Vectorette and Alu-Exon PCR", Genome Res., Vol. 6, pp. 1200-1206 (1996)							
	AC								
	AD								
	AE								
	AF								
	AG								
·	АН								
	AI								
	AJ								
	AK								
	AL								
	АМ								
	AN								
EXAMIN	ER	DATE CONSIDERED							

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.